CA2801020A1 - Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide - Google Patents

Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide Download PDF

Info

Publication number
CA2801020A1
CA2801020A1 CA2801020A CA2801020A CA2801020A1 CA 2801020 A1 CA2801020 A1 CA 2801020A1 CA 2801020 A CA2801020 A CA 2801020A CA 2801020 A CA2801020 A CA 2801020A CA 2801020 A1 CA2801020 A1 CA 2801020A1
Authority
CA
Canada
Prior art keywords
telmisartan
formulation according
diuretic
formulation
stable pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2801020A
Other languages
English (en)
Inventor
Naresh Talwar
Dean Sebastian
Mathew Philip
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmascience Inc
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Priority to CA2801020A priority Critical patent/CA2801020A1/fr
Publication of CA2801020A1 publication Critical patent/CA2801020A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne une préparation pharmaceutique stable contenant du telmisartan, ou un sel pharmaceutiquement acceptable de celui-ci, et un diurétique dispersé dans une matrice. La matrice contient au moins un délitant dans une quantité comprise entre 0,5 % et 20% en poids ; un agent d'amélioration de dissolution présent dans un rapport molaire agent d'amélioration de dissolution - telmisartan compris entre 1:1 et 10:1 ; et un diluant hydro-insoluble dans une quantité comprise entre 15% et 75% en poids et au moins un autre excipient ou adjuvant pharmaceutiquement acceptable dans une quantité comprise entre 0 et 25% en poids.
CA2801020A 2010-05-28 2011-05-27 Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide Abandoned CA2801020A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2801020A CA2801020A1 (fr) 2010-05-28 2011-05-27 Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2,706,292 2010-05-28
CA2706292A CA2706292A1 (fr) 2010-05-28 2010-05-28 Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide
CA2801020A CA2801020A1 (fr) 2010-05-28 2011-05-27 Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide
PCT/CA2011/000621 WO2011147026A2 (fr) 2010-05-28 2011-05-27 Préparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide

Publications (1)

Publication Number Publication Date
CA2801020A1 true CA2801020A1 (fr) 2011-12-01

Family

ID=45004457

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2706292A Abandoned CA2706292A1 (fr) 2010-05-28 2010-05-28 Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide
CA2801020A Abandoned CA2801020A1 (fr) 2010-05-28 2011-05-27 Preparation pharmaceutique stable contenant du telmisartan et de l'hydrochlorothiazide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CA2706292A Abandoned CA2706292A1 (fr) 2010-05-28 2010-05-28 Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide

Country Status (2)

Country Link
CA (2) CA2706292A1 (fr)
WO (1) WO2011147026A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102885789A (zh) * 2012-04-05 2013-01-23 常州制药厂有限公司 一种治疗高血压的复方制剂的制备方法
WO2014068507A1 (fr) * 2012-11-02 2014-05-08 Abbott Healthcare Pvt. Ltd. Compositions pharmaceutiques orales solides de telmisartan essentiellement exemptes de tensioactifs
WO2017106332A1 (fr) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
ES2907489T3 (es) 2015-12-14 2022-04-25 X4 Pharmaceuticals Inc Métodos para el tratamiento del cáncer
HUE060517T2 (hu) 2015-12-22 2023-03-28 X4 Pharmaceuticals Inc Immunhiányos betegség kezelésére szolgáló eljárások
EP3405203A4 (fr) * 2016-01-22 2019-07-24 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017177230A1 (fr) 2016-04-08 2017-10-12 X4 Pharmaceuticals, Inc. Méthodes de traitement du cancer
WO2017223229A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
JP7054529B2 (ja) 2016-06-21 2022-04-14 エックス４ ファーマシューティカルズ， インコーポレイテッド Ｃｘｃｒ４阻害剤およびその使用
CA3027500A1 (fr) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Inhibiteurs de cxcr4 et leurs utilisations
CN107501192A (zh) * 2017-08-15 2017-12-22 中国科学院上海药物研究所 替米沙坦与氢氯噻嗪的共晶
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
JP2023517956A (ja) 2020-03-10 2023-04-27 エックス４ ファーマシューティカルズ， インコーポレイテッド 好中球減少症を処置する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10244681A1 (de) * 2002-09-24 2004-04-08 Boehringer Ingelheim International Gmbh Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
CA2644179C (fr) * 2007-11-21 2018-09-25 Pharmascience Inc. Composition pharmaceutique inedite comprenant une matrice de desintegration
TR200906506A2 (tr) * 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.

Also Published As

Publication number Publication date
CA2706292A1 (fr) 2011-11-28
WO2011147026A2 (fr) 2011-12-01
WO2011147026A3 (fr) 2012-01-26

Similar Documents

Publication Publication Date Title
CA2780428C (fr) Formulations de comprimes de maleate de neratinib
KR100876302B1 (ko) 사실상 비결정질 형태인 텔미사르탄의 제조방법
CA2706292A1 (fr) Une formulation pharmaceutique stable renfermant du telmisartan et de l'hydrochlorothiazide
US20050186274A1 (en) Multilayer tablet
CA2532450C (fr) Combinaisons de chlorthalidone
EP1098634A2 (fr) Formulations bioameliorees comprenant de l'eprosartane dans des formes galeniques solides destinees a une administration orale
EP2252273B1 (fr) Composition pharmaceutique solide incluant un antagoniste non peptidique du récepteur de l'angiotensine ii et un diurétique
KR20070085754A (ko) 안정화된 라미프릴 조성물 및 제조 방법
CA2644179C (fr) Composition pharmaceutique inedite comprenant une matrice de desintegration
TWI586353B (zh) Pharmaceutical preparations containing calcium antagonists and angiotensin II receptor antagonists
KR101931489B1 (ko) 칼슘 길항약／안지오텐신 ｉｉ 수용체 길항약 함유 의약 제제의 제조 방법
KR20110085307A (ko) 난용성 약물을 함유하는 경구 제형
US11260055B2 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2006067601A1 (fr) Compositions pharmaceutiques orales a base d'irbesartan et d'hydrochlorothiazide et procedes de preparation desdites compositions
KR20080100292A (ko) 사실상 비결정질 형태인 텔미사르탄의 제조방법
WO2008008057A1 (fr) Formulation stable comprenant une combinaison d'un médicament sensible à l'humidité et d'un second médicament et procédure de fabrication de celle-ci

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20160504

FZDE Discontinued

Effective date: 20190617